
Artificial Intelligence in COPD
Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.

Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.

Discover the first study designed to analyze the impact of EVLP on the lung microbiome and the local inflammatory response. Understanding the composition, diversity, and functional interactions of the pulmonary microbiome in lung transplants holds promise for personalized respiratory medicine.

La Societat Catalana de Pneumologia (SOCAP) y Chiesi han lanzado la iniciativa ‘Sense Límits’ para concienciar sobre las enfermedades respiratorias, con actividades divulgativas y solidarias como espirometrías, pedaleos solidarios y marchas nórdicas, promoviendo la investigación científica y el cuidado de la salud respiratoria.

This study explores how changes in the respiratory microbiome relate to systemic inflammation in COPD patients. It highlights correlations between bacterial abundance, eosinophilic markers, and airflow limitation severity.

The efficacy and safety of mepolizumab in patients with COPD has been investigated in two placebo-controlled Phase 3 trials, METREX and METREO, and theongoing MATINEE trial.

This article examines exacerbations of COPD, emphasizing the need for identifying distinct etioendophenotypes to develop targeted therapies and improve current modest outcomes.

Insight into the impact of doxycycline in therapeutic trials for COPD, emphasizing the need for careful microbiological monitoring in future interventional trials in patients with COPD

In the general population Persistent Airflow Obstruction (PAO) was largely mild but there are significant phenotypic differences between young and old individuals with PAO

Uncover the prevalence, characteristics, and comorbidities of asthma with airflow obstruction (AFO) in adults over 50. Learn how AFO compares to asthma-only and COPD-only in this comprehensive study.

Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE).